Mutations in the DNA polymerase binding pathway affect the immune microenvironment of patients with small‐cell lung cancer and enhance the efficacy of platinum‐based chemotherapy
Abstract Background Small‐cell lung cancer (SCLC) is characterized by its high malignancy and is associated with a poor prognosis. In the early stages of the disease, platinum‐based chemotherapy is the recommended first‐line treatment and has demonstrated efficacy. However, SCLC is prone to recurren...
Main Authors: | Anqi Lin, Weiming Mou, Lingxuan Zhu, Tao Yang, Chaozheng Zhou, Jian Zhang, Peng Luo |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-12-01
|
Series: | Cancer Innovation |
Subjects: | |
Online Access: | https://doi.org/10.1002/cai2.84 |
Similar Items
-
DNA damage response and repair gene mutations are associated with tumor mutational burden and outcomes to platinum-based chemotherapy/immunotherapy in advanced NSCLC patients
by: Weiguang Gu, et al.
Published: (2023-11-01) -
THSD7B Mutation Induces Platinum Resistance in Small Cell Lung Cancer Patients
by: Yao Z, et al.
Published: (2022-06-01) -
Role of rs873601 Polymorphisms in Prognosis of Lung Cancer Patients Treated with Platinum-Based Chemotherapy
by: Ting Zou, et al.
Published: (2023-11-01) -
The Association Between Genetic Polymorphisms of Transporter Genes and Prognosis of Platinum-Based Chemotherapy in Lung Cancer Patients
by: He J, et al.
Published: (2022-09-01) -
CAMSAP1 Mutation Correlates With Improved Prognosis in Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy
by: Yonglin Yi, et al.
Published: (2022-01-01)